生命科学资讯
生物技术与制药领域的最新动态
Trump’s State of the Union trumpets healthcare greatest hits, but no new policies
Gilead, Merck plan to debut new daily HIV pills
Make way, Camzyos: Cytokinetics touts promising early launch for rival heart drug
LUMI实验室：基于基础模型驱动的自主平台，助力发现用于mRNA递送的可离子化脂质设计方案
LUMI-lab: A foundation model-driven autonomous platform enabling discovery of ionizable lipid designs for mRNA delivery
编辑独脚金内酯激素受体以增强水稻抗病毒沉默能力
Editing strigolactone hormone receptor for robust antiviral silencing in rice
调控网络促进质外体碱化，启动感染部位远端组织的植物免疫。
A regulatory network promotes apoplastic alkalinization to prime plant immunity in tissues distal to site of infection
真菌来源的纤维二糖代谢途径助力T细胞绕过肿瘤内葡萄糖竞争
Fungal-derived cellobiose metabolic pathway fuels T cells to bypass intratumoral glucose competition
ARPA-H拨款高达1.44亿美元用于抗衰老医学研究
ARPA-H designates up to $144M for anti-aging medical research
担忧特朗普的最惠国待遇推进将“摧毁生物技术创新”，中型企业组建联盟反击。
Worried Trump's MFN push will ‘destroy biotech innovation,’ midsize companies form coalition to fight back
查尔斯河出售制造与发现业务，兑现战略转型承诺。
Charles River sells manufacturing and discovery businesses to fulfill promised pivot
2026年2月25日任命与晋升动态
Appointments and advancements for Feb. 25, 2026
2026年2月25日融资动态
Financings for Feb. 25, 2026
2026年2月25日门诊
In the clinic for Feb. 25, 2026
2026年2月25日其他值得关注的新闻
Other news to note for Feb. 25, 2026
2026年2月25日监管动态
Regulatory actions for Feb. 25, 2026
阿尔克梅斯公司首席执行官理查德·波普斯在执掌公司三十年后即将卸任。
Alkermes’ Richard Pops to step down after three-decade run as CEO
查尔斯河实验室出售其CDMO及欧洲发现业务部门。
Charles River sells its CDMO and European discovery businesses
诺和诺德与朗格初创公司签署21亿美元协议，以增强口服药物递送能力。
Novo Nordisk inks $2.1B pact with Langer startup to boost oral drug delivery prowess
辉瑞退出基因疗法后，锁定Beam基因编辑候选药物全球许可权
After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate